-
131.发明公开ＥＧＣＧ를 유효성분으로 함유하는 쇼그렌 증후군, 베체트 증후군, 강직성척추염 또는 루프스의 예방 또는 치료용 조성물 有权用于预防或治疗SJOGREN综合征，BEHCET综合征，包括作为活性成分的EGCG的神经系统性红斑狼疮或系统性红斑狼疮的组合物
公开(公告)号：KR1020110128542A
公开(公告)日：2011-11-30
申请号：KR1020100048052
申请日：2010-05-24
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/353 , A61K31/355 , A23L1/30
CPC classification number: A61K31/353 , A23L33/10 , A23V2002/00 , A23V2200/324 , A61K31/355
Abstract: PURPOSE: A pharmaceutical composition containing EGCG(epigallocatechin gallate) is provided to suppress differentiation of cytotoxic Th17 cells and to prevent or treat Sjogren syndrome, Behcet syndrome, or lupus. CONSTITUTION: A composition for preventing or treating Sjogren syndrome, Behcet syndrome, or lupus contains EGCG(epigallocatechin gallate) compound or salt thereof as an active ingredient. The EGCG suppresses or reduces differentiation of undifferentiated T cells into Th17 cells. A method for activating regulatory T cells comprises a step of treating the EGCG compounds or salt thereof to the T cells(Treg) in vitro. A functional food for treating or preventing Sjogren syndrome, Behcet syndrome, or lupus contains the EGCG compound or salt thereof as an active ingredient. A composition for suppressing immunity contains the EGCG compounds or salt thereof as an active ingredient.
Abstract translation: 目的：提供含有EGCG（表没食子儿茶素没食子酸酯）的药物组合物，以抑制细胞毒Th17细胞的分化，并预防或治疗干燥综合征，白塞综合征或狼疮。 构成：用于预防或治疗干燥综合征，白塞综合征或狼疮的组合物含有EGCG（表没食子儿茶素没食子酸酯）化合物或其盐作为活性成分。 EGCG抑制或减少未分化T细胞分化为Th17细胞。 用于激活调节性T细胞的方法包括在体外将T细胞（Treg）处理EGCG化合物或其盐的步骤。 用于治疗或预防干燥综合征，白塞综合征或狼疮的功能性食物含有EGCG化合物或其盐作为活性成分。 用于抑制免疫的组合物含有EGCG化合物或其盐作为活性成分。
-
公开(公告)号：KR1020110092237A
公开(公告)日：2011-08-17
申请号：KR1020110010999
申请日：2011-02-08
Applicant: 가톨릭대학교 산학협력단
IPC: A61K38/16 , A61K31/7105 , A61P29/00 , A61P37/00
CPC classification number: A61K38/16 , Y10S514/825 , Y10S514/857 , Y10S514/866 , Y10S514/885 , Y10S514/886 , Y10S514/894 , Y10S514/903 , Y10S514/925
Abstract: PURPOSE: A composition containing Grim19 for preventing or treating immune diseases is provided to suppress cytotoxic Th17 cell differentiation and to activate regulatory T cells. CONSTITUTION: A composition for preventing or treating immune diseases contains Grim19 protein as an active ingredient. The Grim19 protein has an amino acid sequence of sequence number 1. The immune diseases are autoimmune diseases, inflammatory diseases, and transplantation rejection diseases of cells, tissues, or organs. A method for activating regulatory T cells comprises a step of treating Grim 19 protein or an expression vector to the T cells. The expression vector contains a polynucleotide encoding Grim19 protein.
Abstract translation: 目的：提供含有用于预防或治疗免疫疾病的Grim19的组合物，以抑制细胞毒性Th17细胞分化并激活调节性T细胞。 构成：用于预防或治疗免疫疾病的组合物含有Grim19蛋白作为活性成分。 Grim19蛋白具有序列号1的氨基酸序列。免疫疾病是细胞，组织或器官的自身免疫疾病，炎性疾病和移植排斥疾病。 用于激活调节性T细胞的方法包括对T细胞处理Grim19蛋白或表达载体的步骤。 表达载体含有编码Grim19蛋白的多核苷酸。
-
133.发明公开
公开(公告)号：KR1020110049627A
公开(公告)日：2011-05-12
申请号：KR1020100025050
申请日：2010-03-22
Applicant: 에이치 엘 지노믹스(주) , 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract is provided to prevent and treat gastrointestinal ulcer. CONSTITUTION: A pharmaceutical composition for preventing or treating gastrointestinal ulcer contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The extract of Vitis vinifera seeds contains 80-130 of procyanidolic value(PCV); 30% or less of (+)catechin and (-) epicatechin; and 95-105% of proanthocyanidin. A method for preparing the Vitis vinifera seed extract comprises: a step of extracting Vitis vinifera seed seeds in a mixture solvent of acetone and water and filtering; a step of distilling liquid and removing acetone; a step of saturating sodium chloride and filtering; a step of extracting the liquid with ethyl acetate and concentrating; and a step of adding chloroform and filtering to obtain precipitate.
Abstract translation: 目的：提供含有葡萄籽提取物的药物组合物，用于预防和治疗胃肠溃疡。 构成：用于预防或治疗胃肠溃疡的药物组合物含有葡萄种子提取物和药学上可接受的载体。 葡萄籽提取物含有原花青素含量（PCV）80-130; 30％以下（+）儿茶素和（ - ）表儿茶素; 和95-105％的原花色素。 一种葡萄种子提取物的制备方法，其特征在于：在丙酮和水的混合溶剂中提取葡萄种子种子并过滤; 蒸馏液并除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯萃取液体并浓缩的步骤; 并加入氯仿和过滤以获得沉淀物的步骤。
-
公开(公告)号：KR1020100117184A
公开(公告)日：2010-11-03
申请号：KR1020090035796
申请日：2009-04-24
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera for preventing or treating osteoarthritis is provided. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoarthritis contains Vitis vinifera extract and pharmaceutically acceptable carrier. Osteoarthritis is caused by aging, obesity or trauma. The Vitis vinifera extract contains 80-130 of procyanidolic value(PCV), 30% or less (+) catechin and (-) epicatechin, and 95-105% of proanthocyanidine. A method for producing Vitis vinifera extract comprises: a step of extracting Vitis vinifera and mixture of acetone and water at room temperature and filtering; a step of distilling remaining liquid and removing acetone; a step of saturating sodium chloride and filtering; a step of extracting with ethyl acetate and concentrating; and a step of adding chloroform and precipitating.
Abstract translation: 目的：提供一种含有葡萄酒的预防或治疗骨关节炎的药物组合物。 构成：用于预防或治疗骨关节炎的药物组合物含有葡萄葡萄提取物和药学上可接受的载体。 骨关节炎是由衰老，肥胖或创伤引起的。 葡萄籽提取物含有原花青素值（PCV）80-130，儿茶素和（ - ）表儿茶素30％以下，原花青素95-105％。 一种葡萄酒提取物的制备方法，其特征在于：在室温下提取葡萄酒和丙酮与水的混合物，过滤; 蒸馏剩余液体并除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯提取并浓缩的步骤; 并加入氯仿和沉淀的步骤。
-
135.发明公开유럽종 포도의 씨 추출물의 제조방법 및 이를 함유하는 류마티스 관절염 예방 또는 치료용 약학 조성물 有权制备VITIS VINIFERA PIP萃取物和药物组合物的方法，用于预防或治疗包含其中的RHEUMATOID ARTHRITIS
公开(公告)号：KR1020090024647A
公开(公告)日：2009-03-09
申请号：KR1020080087109
申请日：2008-09-04
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: A method for preparing extracts from seeds of Vitis Vinifera is provided to reduce the quantity of acetone consumed for extraction by using a mixed solvent of water and acetone while securing a high yield. A method for preparing extracts from seeds of Vitis Vinifera comprises the following steps of: extracting an extract from a mixture of pulverized seeds of the Vitis Vinifera and a acetone/water mixed solvent in a mixing ratio of 1 to 1-2 at a room temperature and filtering the extract; removing the acetone by distilling the obtained extract and saturating the extract with sodium chloride; extracting the saturated extract by ethylacetate and concentrating the extract; and adding chloroform to the concentrated extract to obtain precipitate.
Abstract translation: 提供了一种用于从酿酒酵母的种子制备提取物的方法，以通过使用水和丙酮的混合溶剂来减少用于提取的丙酮消耗量，同时确保高产率。 从酿酒酵母种子提取提取物的方法包括以下步骤：将葡萄酒的粉碎种子和丙酮/水混合溶剂的混合物中的提取物以1至1-2的混合比在室温下萃取 并过滤提取物; 通过蒸馏所得提取物并用氯化钠饱和提取物除去丙酮; 用乙酸乙酯提取饱和提取物，浓缩提取物; 并向浓缩的萃取液中加入氯仿，得到沉淀。
-
Patent Agency Ranking
-
公开(公告)号：KR102256180B1
公开(公告)日：2021-05-26
申请号：KR1020180098779
申请日：2018-08-23
Applicant: 가톨릭대학교 산학협력단
IPC: A61B5/00
Abstract: 본발명은, 연골강도측정장치에대하여개시한다. 이를위해본 발명은, 필기구형상의바디의상단에구비된클립캡에서연골의강도측정선택을이루며, 상기바디의하단에구비된촉캡에서는연골의강도측정을이루며, 측정된강도의표시가바디의표면을통해투시되게하는바디부재와, 상기바디내의축선위치에설치되는측정봉이상기바디의하단으로돌출된상태에서연골에접촉시연골의강도에따른상기측정봉의복귀정도가상기바디의표면에설치되는투시창의기준눈금으로비교판단되게하는측정부재와, 상기바디상단에서상기측정봉의출몰상태가선택되게하는노브와슬리브그리고, 상기측정봉의출몰시제어링을기준으로상기측정봉의상,하양방향에탄성반발력이작용되게하는제어부재를포함하여된 것으로, 수술현장에서수술자의연골에대한강도측정이가능하여환자에게맞는조건적수술을할 수있게된다.
-
公开(公告)号：KR1020210043796A
公开(公告)日：2021-04-22
申请号：KR1020190126394
申请日：2019-10-11
Applicant: 가톨릭대학교 산학협력단 , 주식회사 비피도
IPC: C12N1/20 , A23L33/135 , A61P19/02 , C12R1/01
Abstract: 본발명은비피도박테리움슈도카테눌라툼 (Bifidobacterium pseudocatenulatum) C-RAPO 균주및 이를포함하는류마티스관절염개선용, 치료용또는예방용조성물에관한것으로, 본발명에서새롭게분리한비피도박테리움슈도카테눌라툼 (Bifidobacteriumpseudocatenulatum) C-RAPO는류마티스관절염치료효과가뛰어나므로류마티스관절염치료제또는류마티스관절염개선용프로바이오틱스소재로유용하게이용될수 있다.
-
公开(公告)号：KR1020210033450A
公开(公告)日：2021-03-26
申请号：KR1020210034472
申请日：2021-03-17
Applicant: 가톨릭대학교 산학협력단
Abstract: 본발명은골수유래억제세포(MDSC, myeloid-derived suppressor cells) 및조절 T 세포(regulatory T cell, Treg)를유효성분으로포함하는면역조절용약학적조성물및 이의다양한적용에관한것이다. 본발명의조성물은 Foxp3+Treg 세포및IL-10 유도한 CD1d+CD5+ Breg 세포를증가시키고, IL-17+CD4+T 세포를억제시킴을확인였는바, MDSC 및 Treg의병용처리는각 단독처리보다시너지효과가나타나유의적인면역조절능이존재함을확인하였다. 또한, 상기시너지효과로인하여, 쇼그렌증후군및 이식편대숙주병에유의적인치료효과가확인되어, 관련약학및 식품산업에유용하게이용될수 있다.
-
-
-
-
-
-
-
-
-
Search Results
262
records
(took 0.029 seconds)
